195 related articles for article (PubMed ID: 28460548)
1. Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.
Rapoport B; Smit T
Expert Opin Drug Saf; 2017 Jun; 16(6):697-710. PubMed ID: 28460548
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
[TBL] [Abstract][Full Text] [Related]
3. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
Navari RM
Expert Opin Drug Saf; 2019 Dec; 18(12):1127-1132. PubMed ID: 31622113
[No Abstract] [Full Text] [Related]
4. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
[TBL] [Abstract][Full Text] [Related]
5. IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther; 2018 Dec; 60(1561):e200-e201. PubMed ID: 30653479
[No Abstract] [Full Text] [Related]
6. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
Chasen MR; Rapoport BL
Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C; Slusher BS
Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
[TBL] [Abstract][Full Text] [Related]
8. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
9. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
Rapoport B; van Eeden R; Smit T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
[TBL] [Abstract][Full Text] [Related]
10. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
[TBL] [Abstract][Full Text] [Related]
11. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).
Rashad N; Abdel-Rahman O
Drug Des Devel Ther; 2017; 11():947-954. PubMed ID: 28392676
[TBL] [Abstract][Full Text] [Related]
12. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL; Jordan K; Weinstein C
Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
Zhang Z; Zhang Y; Chen G; Hong S; Yang Y; Fang W; Luo F; Chen X; Ma Y; Zhao Y; Zhan J; Xue C; Hou X; Zhou T; Ma S; Gao F; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
Oncologist; 2018 May; 23(5):603-616. PubMed ID: 29330211
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
16. Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Gilmore J; Bernareggi A
J Clin Pharmacol; 2019 Apr; 59(4):472-487. PubMed ID: 30412271
[TBL] [Abstract][Full Text] [Related]
17. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
Navari RM
Paediatr Drugs; 2017 Jun; 19(3):213-222. PubMed ID: 28447301
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
20. Rolapitant: first global approval.
Syed YY
Drugs; 2015 Nov; 75(16):1941-5. PubMed ID: 26467681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
